Page 55 - Libro de Ponencias Congres SEHH-SETH 2017

tive neoplasms displaying a PDGFRB rearrangement. Eur J Haematol.
2012;89(1):37-41.
19. Cheah CY, Burbury K, Apperley JF, Huguet F, Pitini V, Gardembas M, et al. Pa-
tients with myeloid malignancies bearing PDGFRB fusion genes achieve du-
rable long-term remissions with imatinib. Blood. 2014;123(23):3574-7.
20. Erben P, Gosenca D, Müller MC, Reinhard J, Score J, Del Valle F, et al. Screen- ing for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Hae-
matologica. 2010;95(5):738-44.
21. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, et
al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347(7):481-7.
22. Martín López A, Robledo C, Are M, Benito R, Hernández Sánchez JM, Her- nández Rivas JM. Estudio mediante secuenciación masiva de las noeplasias mieloides con reordenamiento de PDGFRB. En: LVIII Congreso Nacional de la SEHH. Santiago de Compostela; 2016. PC -169.
23. Chen J,Deangelo DJ,Kutok JL,Williams IR,Lee BH,Wadleigh M,et al.PKC412 inhibits the zinc nger 198- broblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004;101(40):14479-84.
24. Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010;41(4):461-76.
25. Savage NM, Johnson RC, Gotlib J, George TI. Myeloid and lymphoid neo- plasms with FGFR1 abnormalities: diagnostic and therapeutic challenges. Am J Hematol. 2013;88(5):427-30.
26. Martínez-Climent JA, Vizcarra E, Benet I, Marugan I, Terol MJ, Solano C, et al. Cytogenetic response induced by interferon alpha in the myeloproliferative disorder with eosinophilia,T cell lymphoma and the chromosomal transloca- tion t(8;13)(p11;q12). Leukemia. 1998;12(6):999-1000.
27. Wehrli M, Oppliger Leibundgut E, Gattiker HH, Manz MG, Müller AMS, Goede JS. Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement. Oncologist. 2017;22(4):480-3.
28. Yamamoto S, Otsu M, Matsuzaka E, Konishi C, Takagi H, Hanada S, et al. Screening of drugs to treat 8p11 myeloproliferative syndrome using patient- derived induced pluripotent stem cells with fusion gene CEP110-FGFR1. PloS One. 2015;10(3):e0120841.
29. Malli T, Buxhofer-Ausch V, Rammer M, Erdel M, Kranewitter W, Rumpold H, et al. Functional characterization, localization, and inhibitor sensitivity of the TPR-
FGFR1 fusion in 8p11 myeloproliferative syndrome. Genes Chromosomes
Cancer. 2016;55(1):60-8.
30. Chase A, Grand FH, Cross NCP. Activity of TKI258 against primary cells and
cell lines with FGFR1 fusion genes associated with the 8p11 myeloprolifera-
tive syndrome. Blood. 2007;110(10):3729-34.
31. Qiu X-H, Li F, Cao H-Q, Shao J-J, Mei J-G, Li H-Q, et al. Activity of broblast
growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against
TPR-FGFR1 fusion. Mol Med Rep. 2017;15(3):1024-30.
32. Kreil S, Adès L, Bommer M, Stegelmann F, Ethell ME, Lubking A, et al. Limit-
ed Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with
FGFR1 Fusion Genes. Blood. 2015;126(23):2812.
33. Bain BJ,Ahmad S.Should myeloid and lymphoid neoplasms with PCM1-JAK2
and other rearrangements of JAK2 be recognized as speci c entities? Br J
Haematol. 2014;166(6):809-17.
34. Rumi E, Milosevic JD, Selleslag D, Casetti I, Lierman E, Pietra D, et al. Ef cacy
of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.Ann Hema-
tol. 2015;94(11):1927-8.
35. Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny H-P, Chase A, et al. Lim-
ited duration of complete remission on ruxolitinib in myeloid neoplasms with
PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol. 2015;94(2):233-8. 36. He R, Greipp PT, Rangan A, Mai M, Chen D, Reichard KK, et al. BCR-JAK2 fu- sion in a myeloproliferative neoplasm with associated eosinophilia. Cancer
Genet. 2016;209(5):223-8.
37. Schwaller J. Modeling ETV6-JAK2-induced leukemia: insights from the zebraf-
ish. Haematologica. 2012;97(12):1783-5.
38. Zaliova M, Moorman AV, Cazzaniga G, Stanulla M, Harvey RC, Roberts KG,
et al. Characterization of leukemias with ETV6-ABL1 fusion. Haematologica.
2016;101(9):1082-93.
39. Falchi L, Mehrotra M, Newberry KJ, Lyle LM, Lu G, Patel KP, et al. ETV6-FLT3
fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leu- kemia. 2014;28(10):2090-2.
40. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781-90.
41. Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, et al. CSF3R T618I is a highly prevalent and speci c mutation in chronic neutro- philic leukemia. Leukemia. 2013;27(9):1870-3.
42. Maxson JE, Tyner JW. Genomics of chronic neutrophilic leukemia. Blood. 2017;129(6):715-22.
LIX Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia / Ponencias
55